

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

## SEQ ID NO.: 1

```
HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 60
DAHKSEVAHRFKDLGEENFKALVLI AFAQYLQQCPFEDHVKLVNEVTEFAKTCVADES AE 120
NCDKSLHTL FGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPE 180
VDVMCTAFHDNEETFLKKYLYEIAARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLL 240
PKLDEL RDEGKASSAKQRLK CASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLT 300
KVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMP 360
ADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVLLLLRLAKTYETTLEK 420
CCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCLEFEQLGEYKFQNALLVRYTKKVPQVS 480
TPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTE 540
SLVNR RPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKA 600
TKEQLKAVMDDFAAFVEKCKADDKETCFAEEGKKLVAASQAALGL 674
```

Figure 6




Figure 7




Figure 8

SEQ ID NO: 3 anti-NOGO mAb Heavy chain

MGWSCIILFL VATATGVHSQ VQLVQSGAEV KKPASVKVS CKASGYTFTS YWMHWVRQAP  
GQGLEWIGNI NPSNGGTNYN EKFKSKATMT RDTSTSTAYM ELSSLRSEDV AVYYCELMQG  
YWGQGTLLTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS  
GVHTFPAVLQ SSGLYSLSSV VTPSSSLGT QTYICNVNHK PSNTKVDKKV EPKSCDKTHT  
CPPCPAPELA GAPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH  
NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE  
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP PVLDSDGSFF  
LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP GK

SEQ ID NO: 4 anti-NOGO mAb light chain

MGWSCIILFL VATATGVHSD IVMTQSPLSN PVTLGQPVSI SCRSSKSLLY KDGKTYLNWF  
LQRPQGSPQL LIYLMSTRAS GVPDRFSGGG SGTDFTLKIS RVEAEDVGVY YCQQLVEYPL  
TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS  
GNSQESVTEQ DSKDSTYSLV STLTLKADY EKHKVYACEV THQGLSSPVT KSFNRGEC

Figure 9

SEQ ID NO: 5 anti-TNFR1 dAb

EVQLLES GGG LVQPGGSLRL SCAASGFTFA HETMVWVRQA PGKGLEWVSH IPPDGQDPFY  
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYHCALLP KRGPWFYDWG QGTLVTVSS

5

Figure 10

SEQ ID NO: 6 IL18

YFGKLESKLS VIRNLNDQVL FIDQGNRPLF EDMTDSDCRD NAPRTIFIIS

MYKDSQPRGM AVTISVKCEK ISTLSCENKI ISFKEMNPPD NIKDTKSDII

FFQRSVPGHD NKMQFESSY EGYFLACEKE RDLFKLILKK EDELGDRSIM

FTVQNED

Figure 11

SEQ ID NO: 7 anti-IL5 mAb Heavy chain

QVTLRESGPA LVKPTQTLTL TCTVSGFSLT SYSVHWVRQP PGKGLEWLGV  
IWASGGTDYN SALMSRLSIS KDTSRNQVVL TMTNMDPVDV ATYYCARDPP  
SSLLRLDYWG RGTPVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  
YFPEPVTVSW NSGALTSGVH TFPVQLQSSG LYSLSVVTV PSSSLGTQTY  
ICNVNHHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS  
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL  
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK

SEQ ID NO: 8 anti-IL5 mAb light chain

DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSGNQKNYLA WYQQKPGQPP  
KLLIYGASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQNVHSF  
PFTFGGGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA  
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEEKHKVYAC  
EVTHQGLSSP VTKSFNRGEC

Figure 12

SEQ ID NO: 9 anti-CD20 VH

MFLGLSWIFL LAILKGVQCE VQLVESGGGL VPQGRSLRLS CAASGFTFND  
YAMHWVRQAP GKGLEWVSTI SWNSGSIGYA DSVKGRFTIS RDNAKKSLEYL  
QMNSLRAEDT ALYYCAKDIQ YGNYYYGMDV WGQGTTVTVS S

SEQ ID NO: 10 anti-CD20 VL

MEAPAQLLFL LLLWLPDTTG EIVLTQSPAT LSLSPGERAT LSCRASQSVS  
SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP  
EDFAVYYCQQ RSNWPITFGQ GTRLEIK